#drug pricing

An unusual alliance among senators emerged in the push to allow for the importation of drugs from Canada and the United Kingdom.

The court sided with the hospitals, which challenged a $1.6 billion Trump-era cut to 340B Medicare reimbursements.

Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.

Bristol Myers Squibb agrees to pay $11 million. The 2019 class-action lawsuit filed by AIDS activists includes several other drugmakers.

President Biden outlined domestic policy priorities that directly impact people living with HIV.

HIV, hepatitis and LGBTQ advocates lead the charge. Plus, a study suggests that long-acting injectable PrEP isn’t cost effective.

Yes! The Mark Cuban Cost Plus Drug Company sells cheaper generic drugs for diabetes, cancer, high blood pressure, HIV, hepatitis and more.

AIDS United’s working group of safety net providers weighs in on ending the epidemic.

The documentary short “Right to Try” follows Jeffrey Drew as he participates in an experimental and controversial treatment to cure HIV.

AIDS United’s working group of safety-net providers advances health equity—with help from the federal 340B Discount Drug Program.

The availability of multiple, low-cost generic versions of PrEP should be good news for access. But will it be?

A letter from 124 patient groups urges the White House to make drugs more affordable—and spells out how it can do so.

The new Avita pharmacy specializes in services related to HIV, PrEP, LGBTQ issues and the 340B Drug Pricing Program.

Watch AIDS advocates urge the governor not to abandon efforts to combat HIV, hepatitis and opioid overdoses.

The first generic Truvada is now available in the United States.

Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.